Viridian Therapeutics, Inc.\DE
In the published model solve dated 2026-Q2, anchored at $21.05, Viridian Therapeutics, Inc.\DE (VRDN) is priced for today's economics sustained for ~18.0 years. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed June 28, 2026 from SEC EDGAR filings.
- Viridian just crossed the line from clinical-stage biotech to commercial company: on June 25, 2026 the FDA approved Lumvoa (veligrotug), its IV antibody for thyroid eye disease, and the company began launching immediately to a target of about 2,000 core prescribers. - The prize is Amgen's Tepezza market, which generated about $1.9 billion last year. Viridian's Phase 3 data showed a placebo-adjusted proptosis resolution rate of 43% against the 28% reported in the Tepezza studies, and a subcuta
Is VRDN overvalued? See what's priced in →
216 institutional managers reported holding VRDN in 13F filings for the quarter ended 2026-03-31. 38 opened new positions that quarter. Held by FMR (Fidelity), BlackRock, Vanguard Group, among others. On the short side, 15.0M shares were sold short as of the 2026-06-15 count, about 18% of shares outstanding (10.1 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
Open-market insider buys at VRDN over the trailing three years: 2024: 4 buys totaling $40.62M; 2025: 1 buy totaling $10.00M. 7 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
VRDN's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-11 | -0.5% | -10.2% |
| 2023-08-09 | -0.3% | -31.0% |
| 2023-11-14 | +10.6% | +45.3% |
| 2024-05-09 | -8.1% | -6.9% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
VRDN's latest 8-K filings: 2026-08-06 (items 2.02, 9.01); 2026-06-29 (items 7.01, 8.01, 9.01); 2026-06-03 (items 5.07); 2026-05-28 (items 1.02); 2026-05-26 (items 1.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: June 28, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.